CANbridge Pharma Overview
- Founded
-
2012
- Status
-
Public
- Employees
-
183
- Stock Symbol
-
01228
- Share Price
-
$0.50
- (As of Monday Closing)
CANbridge Pharma General Information
Description
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
HKG
Primary Office
- Suite 301,3F,Timeloit, No. 17 RongChuang Road
- Chaoyang District
- Beijing
- China
+86 010 0000 0000
CANbridge Pharma Timeline
CANbridge Pharma Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.50 | $0.49 | $0.46 - $1.28 | $211M | 424M | 19.1K | -$1.77 |
CANbridge Pharma Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 821,444 | 821,444 | ||
| Revenue | 4,826 | 4,826 | 1,742 | 213 |
| EBITDA | (164,289) | (164,289) | (119,470) | (30,811) |
| Net Income | (166,795) | (166,795) | (122,462) | (31,503) |
| Total Assets | 140,023 | 140,023 | 89,749 | 12,656 |
| Total Debt | 8,174 | 8,174 | 7,178 | 10,044 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
CANbridge Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CANbridge Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and c
Pharmaceuticals
Beijing, China
183
As of 2021
00000
0000
0000-00-00
00000000
00000
000000
m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000 000000000
Saint-Julien- en-Genevois, France
00
As of 0000
000.00
0000
0000-00-00
000000&0
000.00
000000
cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000000000000
San Francisco, CA
000
As of 0000
00000
0.000
0000-00-00
000000&0
00000
Add Comparison
CANbridge Pharma Competitors (56)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genkyotex | Corporate Backed or Acquired | Saint-Julien- en-Genevois, France | 00 | 000.00 | 000000&0 | 000.00 |
| 000000000 00000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
| 000000000 00000000 | Formerly VC-backed | Guangzhou, China | 000.00 | 00000000000 | ||
| 0000000 0000000000 | Formerly VC-backed | Shanghai, China | 000 | 00000 | 00000000 | 00000 |
| 000 000000000000 | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
CANbridge Pharma Patents
CANbridge Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3644062-A4 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Pending | 22-Jun-2017 | 0000000000 | 0 |
| EP-3644062-A1 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Pending | 22-Jun-2017 | 000000000 | |
| US-20210025006-A1 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Pending | 22-Jun-2017 | 000000000000 | |
| JP-2020524808-A | Methods and kits for predicting esophageal cancer response to anti-erbb3 antibody treatment | Pending | 22-Jun-2017 | G01N33/57407 |
CANbridge Pharma Executive Team (13)
CANbridge Pharma Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Guangping Gao Ph.D | Self | Board Member | 000 0000 |
| Mark Bamforth | CANbridge Pharma | Board Member | 000 0000 |
| Qun Xue Ph.D | CANbridge Pharma | Founder, Chief Executive Officer and Chairman | 000 0000 |
CANbridge Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
CANbridge Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|